Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Authors:
Open Access
- 11 September 2022
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (15) , 6665-6681
Abstract
Rationale: Although stapled peptides offer a powerful solution to overcome the susceptibility of linear peptides to proteolytic degradation and improve their ability to cross membranes, an efficient and durable disease treatment strategy has not yet been developed due to the inevitable elimination of peptide inhibitors and rapid accumulation of target proteins.Keywords
This publication has 41 references indexed in Scilit:
- Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyProceedings of the National Academy of Sciences, 2013
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α InteractionJournal of the American Chemical Society, 2012
- Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX InteractionsJournal of Molecular Biology, 2010
- Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMXJournal of Biological Chemistry, 2010
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMXProceedings of the National Academy of Sciences, 2009
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences, 2008
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- Structural basis for the recognition of hydroxyproline in HIF-1α by pVHLNature, 2002
- Mdm2 promotes the rapid degradation of p53Nature, 1997